Moderna, Inc.
MRNA · Nasdaq
MRNA · Nasdaq
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $1.94B | $3.24B | $6.85B | $19.26B | $18.47B | $803.00M | $60.21M | $135.07M |
| Cost of Revenue | $868.00M | $1.46B | $4.69B | $5.42B | $2.62B | $8.00M | $0.00 | $0.00 |
| Research & Development | $3.13B | $4.54B | $4.84B | $3.29B | $1.99B | $1.37B | $496.00M | $454.08M |
| Selling, General & Administrative | $1.02B | $1.17B | $1.55B | $1.13B | $567.00M | $188.00M | $110.00M | $94.25M |
| Operating Expenses | $5.02B | $7.18B | $11.09B | $9.84B | $5.17B | $1.57B | $605.93M | $548.33M |
| Operating Income | -$3.07B | -$3.94B | -$4.24B | $9.42B | $13.30B | -$763.00M | -$546.00M | -$413.27M |
| Other Income / (Expense) | -$8.00M | -$87.00M | -$124.00M | -$45.00M | -$29.00M | -$6.00M | -$8.00M | $1.83M |
| Income Before Taxes | -$2.77B | -$3.61B | -$3.94B | $9.57B | $13.29B | -$744.00M | -$515.00M | -$384.41M |
| Provision for Income Taxes | $54.00M | -$46.00M | $772.00M | $1.21B | $1.08B | $3.00M | -$1.00M | $326.00K |
| Net Income | -$2.82B | -$3.56B | -$4.71B | $8.36B | $12.20B | -$747.00M | -$514.00M | -$384.73M |
| Basic EPS | -$7.26 | -$9.28 | -$12.33 | $21.26 | $30.31 | -$1.96 | -$1.55 | — |
| Diluted EPS | -$7.26 | -$9.28 | -$12.33 | $20.12 | $28.29 | -$1.96 | -$1.55 | — |
| Basic Shares Outstanding | 389.00M | 384.00M | 382.00M | 394.00M | 403.00M | 381.00M | 331.00M | — |
| Diluted Shares Outstanding | 389.00M | 384.00M | 382.00M | 416.00M | 431.00M | 381.00M | 331.00M | — |
| Period | Consensus EPS | Low | High | Estimates | Revisions |
|---|---|---|---|---|---|
| Dec 2026 | -$6.18 | -$6.60 | -$5.82 | 8 | ↑5 ↓1 |
| Dec 2027 | -$4.67 | -$7.11 | -$3.24 | 10 | ↑5 ↓3 |
| Dec 2028 | -$1.96 | -$3.93 | $0.53 | 6 | ↑2 ↓0 |
| Dec 2029 | $3.51 | -$1.69 | $11.69 | 3 | ↑0 ↓0 |
